Top stories from the Proactive Investors UK newsroom.
Redx Pharma (LON:REDX) has agreed to sell its treatment for mutant tumours to US group Jazz Pharmaceuticals for US$3.5mln plus up to a further US$203mln in milestones. Jazz will be responsible for all future development, regulatory, manufacturing and commercialisation activities.
Simec Atlantis (LON:SAE) says its MeyGen project off the coast of Scotland has managed the longest period of uninterrupted electricity generation ever seen from a tidal wave project. MeyGen has generated revenues of £1.85mln this year.
Mobile commerce group Bango (LON:BGO) moved into profitability in the second quarter of 2019 as user spend through its platform soared again. Revenues in the half year rose 64% to £4.3mln.
Feedback PLC (LON:FDBK) says it is prioritising its Cadran system ahead of its TexRAD technology for uncovering biomarkers in medical images. The change of tack follows a strategic review by new chief executive Tom Oakley, who believes Cadran can become the go-to method of securely sharing patient information by mobile phone or tablet.
Barratt’s profits this year will be ahead of expectations at around £910mln after a strong end to the year and better margins. Forward sales for 2020 are 20% higher at £2.6bn.